229. 肺胞蛋白症(自己免疫性又は先天性) Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details
臨床試験数 : 43 / 薬物数 : 34 - (DrugBank : 8) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14
Showing 1 to 10 of 43 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2020-001263-85-NL (EUCTR) | 19/07/2021 | 08/10/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution byinhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim neb ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis(aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Netherlands;Germany;Japan;Korea, Republic of United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Netherlands;G ... | ||
2 | NCT04811274 (ClinicalTrials.gov) | June 7, 2021 | 19/3/2021 | Macrophages, GM-CSF and MARS Proteinosis | Study of Macrophage Function and of the GM-CSF Signaling Pathway in Alveolar Proteinosis by Mutations of the MARS Gene Study of Macrophage Function and of the GM-CSF Signaling Pathway in Alveolar Proteinosis by Mutation ... | Pulmonary Alveolar Proteinosis (PAP);MARS;Genetic Mutation | Biological: Blood collection;Biological: Bronchoalveolar lavage fluid collection | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | N/A | 17 Years | All | 20 | France | |
3 | NCT04544293 (ClinicalTrials.gov) | May 10, 2021 | 3/9/2020 | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinos ... | A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb ... | Autoimmune Pulmonary Alveolar Proteinosis | Drug: Molgramostim;Drug: Placebo | Savara Inc. | NULL | Recruiting | 18 Years | N/A | All | 160 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;United Kingdom United States;Australia;Belgium;Canada;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of; ... |
4 | EUCTR2020-001263-85-BE (EUCTR) | 08/03/2021 | 04/12/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution byinhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim neb ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis(aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Germany;Netherlands;Japan;Korea, Republic of United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Germany;Nethe ... | ||
5 | EUCTR2020-001263-85-IE (EUCTR) | 08/02/2021 | 08/10/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim neb ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis(aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Ireland;Turkey;Italy;United Kingdom;France;Canada;Belgium;Poland;Romania;Germany;Netherlands;Japan;Korea, Republic of United States;Ireland;Turkey;Italy;United Kingdom;France;Canada;Belgium;Poland;Romania;Germany;Nethe ... | ||
6 | EUCTR2020-001263-85-DE (EUCTR) | 27/01/2021 | 16/10/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim neb ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis(aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Ireland;Turkey;Italy;United Kingdom;France;Canada;Belgium;Poland;Romania;Germany;Netherlands;Japan;Korea, Republic of United States;Ireland;Turkey;Italy;United Kingdom;France;Canada;Belgium;Poland;Romania;Germany;Nethe ... | ||
7 | EUCTR2020-001263-85-PL (EUCTR) | 16/12/2020 | 19/11/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim neb ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis(aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | Canada;Poland;Belgium;Romania;Germany;Netherlands;Japan;Korea, Republic of;France;Italy;United Kingdom;Turkey;Ireland;United States Canada;Poland;Belgium;Romania;Germany;Netherlands;Japan;Korea, Republic of;France;Italy;United Kingd ... | ||
8 | EUCTR2020-001263-85-IT (EUCTR) | 18/11/2020 | 24/05/2021 | A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosiswill ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim neb ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis(aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution Product Code: [na] INN or Proposed INN: 00201600 | SAVARA APS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Korea, Democratic People's Republic of;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Germany;Netherlands;Japan;Korea, Republic of United States;Korea, Democratic People's Republic of;Ireland;Turkey;United Kingdom;Italy;France;Cana ... | ||
9 | NCT04326036 (ClinicalTrials.gov) | March 25, 2020 | 26/3/2020 | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection | Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infectio ... | Pulmonary Alveolar Proteinosis;COPD;Idiopathic Pulmonary Fibrosis;Viral Pneumonia;Coronavirus Infection;Interstitial Lung Disease Pulmonary Alveolar Proteinosis;COPD;Idiopathic Pulmonary Fibrosis;Viral Pneumonia;Coronavirus Infect ... | Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Cent ... | Black Tie Medical, Inc. | Robert W. Alexander, MD | Enrolling by invitation | 18 Years | 90 Years | All | 10 | Early Phase 1 | United States |
10 | NCT03887169 (ClinicalTrials.gov) | September 16, 2019 | 12/3/2019 | Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. Administration of Methionine in Patients With Pulmonary Alveolar Proteinosisby Mutation of the MARS ... | Oral or Enteral Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. Oral or Enteral Administration of Methionine in Patients With Pulmonary Alveolar Proteinosisby Mutat ... | Pulmonary Alveolar Proteinosis;Mutation Ala393Thr of the MARS Gene;mutationSer567Leu of the MARS Gene Pulmonary Alveolar Proteinosis;Mutation Ala393Thr of the MARS Gene;mutationSer567Leu of the MARS Gen ... | Drug: Methionine;Drug: Vitamin B12, B9, B6, C supplementation;Diagnostic Test: Methionine/homocysteine Dosage;Diagnostic Test: Thoracic CT scan;Diagnostic Test: Abdominal and liver ultrasound.;Diagnostic Test: Brain MRI Drug: Methionine;Drug: Vitamin B12, B9, B6, C supplementation;Diagnostic Test: Methionine/homocystei ... | Assistance Publique - Hôpitaux de Paris | NULL | Completed | N/A | 18 Years | All | 3 | Phase 1/Phase 2 | France |